Discordance between EGFR expression and clinicopathologic parameters of colorectal adenocarcinoma in Taiwan

Chinese Journal of Physiology

Volumn 55, Issue 5, 2012, Pages 1-9

  Tsai, Wen Chiuan ^a   Lin, Chih Kung ^a   Lee, Herng Sheng ^a   Chen, Ann ^a   Nieh, Shin ^a   Yu, Cheng Ping ^a   Wu, Chang Chieh ^b   Jao, Shu Wen ^b   Jin, Jong Shiaw ^c  

^a Division of Colon and Rectal Surgery   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

Author keywords

Colorectal adenocarcinoma; EGFR; Ki67; P53; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TAIWAN; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

EID: 84867147591     PISSN: 03044920     EISSN: 26660059     Source Type: Journal    
DOI: 10.4077/CJP.2012.BAA061     Document Type: Article

References (39)

1. Aimes, R.T., Zijlstra, A., Hooper, J.D., Ogbourne, S.M., Sit, M.L., Fuchs, S., Gotley, D.C., Quigley, J.P. and Antalis, T.M. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb. Hemost. 89: 561-572, 2003.
2. Allegra, C.J., Paik, S., Colangelo, L.H., Parr, A.L., Kirsch, I., Kim, G., Klein, P., Johnston, P.G., Wolmark, N. and Wieand, H.S. Prognostic value of thymidylate synthase, Ki67, and p53 in patients with Dukes B and C colon cancer: a national cancer institute-national surgical adjuvant breast and bowel project collaborative study. J. Clin. Oncol. 21: 241-250, 2003.
3. Arber, N., Hibshoosh, H., Yasui, W., Neugut, A.I., Hibshoosh, A., Yao, Y., Sgambato, A., Yamamoto, H., Shapira, I., Rosenman, D., Fabian, I., Weinstein, I.B., Tahara, E. and Holt, P.R. Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel. Cancer Epiderm. Biomar. 8: 1101-1105, 1999.
4. Benaud, C., Dickson, R.B. and Lin, C.Y. Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur. J. Biochem. 268: 1439-1447, 2001.
5. Benaud, C.M., Oberst, M., Dictson, R.B. and Lin, C.Y. Deregulated activation of matriptase in breast cancer cells. Clin. Exp. Metastasis 19: 639-649, 2002.
6. Berenzi, A., Benetti, A., Bertalot, G., Rodolfi, A., Portolani, N., Giulini, S.M., Pulcini, G., Vinco, A. and Tiberio, G. Ki67 immunohistochemical evaluation in colorectal cancer and normal colonic mucosa. Possible clinical application. Pathologica 84: 155-163, 1992.
7. Bhargava, R., Chen, B., Klimstra, D.S., Saltz, L.B., Hedvat, C., Tang, L.H., Gerald, W., Teruya-Feldstein, J., Paty, P.B., Qin, J. and Shia, J. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer 106: 1857-1862, 2006.
8. Cagir, B., Nagy, M.W., Topham, A., Rakinic, J. and Fry, R.D. Ad-enosquamous carcinoma of the colon, rectum, and anus: epidemiology, distribution, and survival characteristics. Dis. Colon. Rectum 42: 258-263, 1999.
9. Cerottini, J.P., Caplin, S., Pampallona, S. and Givel, J.C. Prognostic factors in colorectal cancer. Oncol. Rep. 6: 409-414, 1999.
10. D'Errico, A., Garbisa, S., Liotta, L.A., Castronovo, V., Stetler-Stevenson, W.G. and Grigioni, W.F. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod. Pathol. 4: 239-246, 1991.
11. Ding, H.F. and Fisher, D.E. Mechanisms of P53-mediated apoptosis. Crit. Rev. Oncog. 9: 83-98, 1998.
12. El-Zammar, O.A., Zhang, S. and Katzenstein, A.L. Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopatho-logic features. Diagn. Mol. Pathol. 18: 133-137, 2009.
13. Favis, R., Huang, J., Gerry, N.P., Culliford, A., Paty, P., Soussi, T. and Barany, F. Harmonized microarray/mutation scanning analysis of TP53 mutation in undissected colorectal tumors. Hum. Muta. 24: 63-75, 2004.
14. Ferrara, N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat. 36: 127-137, 1995.
15. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82: 4-6, 1990.
16. Galizia, G., Ferraraccio, F., Lieto, E., Orditura, M., Castellano, P., Imperatore, V., Romano, C., Vollaro, M., Agostini, B., Pignatelli, C. and De Vita, F. Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery. Dis. Colon Rectum 47: 1904-1914, 2004.
17. Gerdes, J., Lemke, H., Baisk, H., Wacker, H.H., Schwab, U. and Stein, H. Cell cycle analysis of the cell proliferation associated human nuclear antigen defined by the monoclonal antiboby Ki67. J. Immunol. 133: 1710-1715, 1984.
18. Gervaz, P., Cerottini, J.P., Bouzourene, H., Hahnloser, D., Doan, C.L., Benhattar, J., Chaubert, P., Secic, M., Gillet, M. and Carethers, J.M. Comparison of microsatellite instability and chromosomal instability in predicting survival of patients with T3N0 colorectal cancer. Surgery 131: 190-197, 2002.
19. Goldstein, N.S. and Armin, M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92: 1331-1346, 2001.
20. Graziano, F. and Cascinu, S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Duke's B colorectal cancer patients: how much evidence is enough. Ann. Oncol. 14: 1026-1038, 2003.
21. Harris, C.C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. (Bathesda) 88: 1442-1455, 1996.
22. Hemilton, S.R. and Aaltonen, L.A. WHO classification of tumors: tumors of the digestive system. Lyon: IRAC 105-119, 2000.
23. He, T.C., Sparks, A.B., Rago, C., Hermeking, H., Zawel, L., da Costa, L.T., Morin, P.J., Vogelstein, B. and Kinzler, K.W. Identification of c-myc as a target of the APC pathway. Science 281: 1509-1512, 1998.
24. Hu, D.N., Hwang, S.M., Lin, X.Z., Yang, P.Y., Tsai, C.H., Huang, Q., Huang, H.Y. and Hwang, M.H. Isolation and characterization of two novel colon cancer cell lines from Chinese patients. In Vitro Cell Dev. Biol. Anim. 43: 105-108, 2007.
25. Kyzer, S. and Gordon, P.H. Determination of proliferative activity in colorectal carcinoma using monoclonal antibody Ki67. Dis. Colon Rectum 40: 322-325, 1997.
26. Lam, J.S., Belldegrum, A.S. and Figlin, R.A. Tissue array-based predictions of pathobiology, prognosis and response to treatment for renal cell carcinoma therapy. Clin. Cancer Res. 10: 6304s-6309s, 2004.
27. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
28. McKay, J.A., Douglas, J.J., Ross, V.G., Curran, S., Ahmed, F.Y., Loane, J.F., Murray, G.I. and McLeod, H.L. Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clin. Cancer Res. 6: 1113-1118, 2000.
29. Mcleod, H.L. and Murray, G.I. Tumor markers of prognosis in colorectal cancer. Brit. J. Cancer 79: 191-203, 1999.
30. Nasif, W.A., El-Emshaty, H.M., Tabll, A., Elmasry, S.A., Attallah, A.M. and Gad Elhak, N.A. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma. Hepatogastroenterology 51: 1001-1006, 2004
31. Nicholson, R.I., Gee, J.M. and Harper, M.E. EGFR and cancer prognosis. Eur. J. Cancer 37: S9-S15, 2001.
32. Perletti, G., Marras, E., Dondi, D., Osti, D., Congiu, T., Ferrarese, R., de Eguileor, M. and Tashjian, A.H. Jr. p21(Waf1/Cip1) and p53 are downstream effectors of protein kinase C delta in tumor suppression and differentiation in human colon cancer cells. Int. J. Cancer 113: 42-53, 2005.
33. Perrone, G., Vincenzi, B., Sanini, D., Verzi, A., Tonini, G., Vetrani, A. and Rabitti, C. Correlation of p53 and bcl-2 expression with vascular growth factor (VEGF), microvessel density (MVD) and clinicopathological features in colon cancer. Cancer Letters 208: 227-234, 2004.
34. Petersen, S., Thames, H.D., Nieder, C., Petersen, C. and Baumann, M. The results of colorectal cancer treatment by p53 status: a treatment-specific overview. Dis. Colon Rectum 44: 322-334, 2001.
35. Potter, J.D. Colorectal cancer: moleculaes and population. J. Natl. Cancer Inst. 91: 916-932, 1999.
36. Resnick, M.B., Routhier, J., Konlin, T., Sabo, E. and Pricolo, V.E. Epidermal growth factor receptor, c-Met, β-Catinin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin. Cancer Res. 10: 3069-3075, 2004.
37. Salomon, D.S., Brandt, R., Ciardiello, F. and Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19: 183-232, 1995.
38. Sasaki, S., Masaki, T., Umetani, N., Futakawa, N., Ando, H. and Muto, T. Characteristics in primary signet-ring cell carcinoma of the colorectum, from clinicopathological observations. Jpn. J. Clin. Oncol. 28: 202-206, 1998.
39. Thomas, G.V., Szigeti, K., Murphy, M., Draetta, G., Pagano, M. and Loda, M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am. J. Pathol. 153: 681-687, 1998.